oxidopamine has been researched along with Left Ventricular Hypertrophy in 1 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| " To assess whether these differential structural effects do translate into different effects on LV function and on heart failure mortality, Bd or sham Bd 8-week-old rats were randomized to vehicle treatment (Vh), chemical sympathectomy ([Sx] 6-hydroxydopamine, 150 mg/kg IP twice a week), beta-adrenoceptor blockade (propranolol [Pro], 40 mg/kg per day PO), or alpha-adrenoceptor blockade (doxazosin [Dox], 5 mg/kg per day PO)." | 3.73 | Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. ( Busca, G; Cesana, F; Clari, F; Ferrari, AU; Ferrero, I; Gatti, C; Janetti, MB; Mancia, G; Palladini, G; Perlini, S; Tozzi, R; Vezzoli, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perlini, S | 1 |
| Ferrero, I | 1 |
| Palladini, G | 1 |
| Tozzi, R | 1 |
| Gatti, C | 1 |
| Vezzoli, M | 1 |
| Cesana, F | 1 |
| Janetti, MB | 1 |
| Clari, F | 1 |
| Busca, G | 1 |
| Mancia, G | 1 |
| Ferrari, AU | 1 |
1 other study available for oxidopamine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Aorta, Abdominal; Blood Pressure | 2006 |